Our results demonstrate that targeting O-glycosylated “dynamic neoepitopes” found in the membrane-tethered MUC1 is a promising therapeutic strategy for improving the treatment outcome of patients with pancreatic cancer. Here, MUC1 is linked to familial pancreatic carcinoma.